Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $8.2 million
Deal Type : Private Placement
Vivani Medical Announces $8.25M Private Placement Equity Financing
Details : The net proceeds from the private placement will used to support the clinical development of NPM-139 (semaglutide), which is being evaluated for the treatment of obesity.
Product Name : NPM-139
Product Type : Peptide
Upfront Cash : Undisclosed
March 27, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $8.2 million
Deal Type : Private Placement
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Reports Positive Preclinical Data on Semaglutide Implant
Details : NPM-139 is a subdermal semaglutide implant, currently under clinical development for chronic weight management in obese and overweight individuals.
Product Name : NPM-139
Product Type : Peptide
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Semaglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Medical Announces First Human Clinical Trial with GLP-1 Implant
Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with obesity and type-2 diabetes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Medical Updates on NPM-115 GLP-1 Obesity Implant Program Development
Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
November 07, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Medical Gets Regulatory Clearance for GLP-1 Implant Trial in Obese Patients
Details : NPM115 (exenatide) implant i is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Clears Vivani's IND for NPM-119 Drug Implant
Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
June 13, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Medical Announces Positive Preclinical Results with GLP-1 Liver Implant
Details : NPM-119 (exenatide) is a GLP-1 agonist miniature long-term subdermal implant, which is currently being evaluated for the treatment of patients with type-2 diabetes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
April 09, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vivani Medical Reports Positive NPM-115 Weight Loss Data Comparable to Ozempic®/Wegovy®
Details : NPM-115 (exenatide implant) is a GLP-1R (Glucagon-like peptide 1 receptor) agonists, peptide drug, which is being evaluated for the chronic weight management in obesity patients.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Inapplicable
February 28, 2024
Lead Product(s) : Exenatide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Second Sight Medical Products
Deal Size : Undisclosed
Deal Type : Merger
Details : Upon completion of the merger, the Company has to advance the development of Vivani’s portfolio, which includes lead asset NPM-119 (exenatide implant), into clinical-stage development for the treatment of patients with Type 2 diabetes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : $55.0 million
August 30, 2022
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Second Sight Medical Products
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Nano Precision Medical
Deal Size : Undisclosed
Deal Type : Merger
Details : Nano Precision Medical, leveraging its proprietary NanoPortalTM drug implant technology, is creating a portfolio of new drugs including NPM’s lead program, NPM-119, that address medication non-adherence, a leading reason for poor clinical outcomes.
Product Name : NPM-115
Product Type : Peptide
Upfront Cash : Undisclosed
July 02, 2022
Lead Product(s) : Exenatide
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Nano Precision Medical
Deal Size : Undisclosed
Deal Type : Merger